Literature DB >> 11171127

Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes.

S R Hawtin1, H C Howard, M Wheatley.   

Abstract

The effects of the peptide hormone oxytocin are mediated by oxytocin receptors (OTRs) expressed by the target tissue. The OTR is a member of the large family of G-protein-coupled receptors. Defining differences between the interaction of agonists and antagonists with the OTR at the molecular level is of fundamental importance, and is addressed in this study. Using truncated and chimaeric receptor constructs, we establish that a small 12-residue segment in the distal portion of the N-terminus of the human OTR provides important epitopes which are required for agonist binding. In contrast, this segment does not contribute to the binding site for antagonists, whether peptide or non-peptide. It does, however, have a role in agonist-induced OTR signalling. Oxytocin is also an agonist at the vasopressin V(1a) receptor (V(1a)R). A chimaeric receptor (V(1a)R(N)-OTR) was engineered in which the N-terminus of the OTR was substituted by the corresponding, but unrelated, sequence from the N-terminus of the V(1a)R. We show that the V(1a)R N-terminus present in V(1a)R(N)-OTR fully restored both agonist binding and intracellular signalling to a dysfunctional truncated OTR construct. The N-terminal segment does not, however, contribute to receptor-selective agonism between the OTR and the V(1a)R. Our data establish a key role for the distal N-terminus of the OTR in providing agonist-specific binding epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171127      PMCID: PMC1221676          DOI: 10.1042/0264-6021:3540465

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Identification of residues involved in ligand binding to the neurokinin-2 receptor.

Authors:  R R Huang; P P Vicario; C D Strader; T M Fong
Journal:  Biochemistry       Date:  1995-08-08       Impact factor: 3.162

2.  The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions.

Authors:  B Mouillac; B Chini; M N Balestre; J Elands; S Trumpp-Kallmeyer; J Hoflack; M Hibert; S Jard; C Barberis
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

3.  1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

Authors:  P D Williams; B V Clineschmidt; J M Erb; R M Freidinger; M T Guidotti; E V Lis; J M Pawluczyk; D J Pettibone; D R Reiss; D F Veber
Journal:  J Med Chem       Date:  1995-11-10       Impact factor: 7.446

Review 4.  Molecular Endocrinology of the oxytocin receptor.

Authors:  T Kimura; F Saji
Journal:  Endocr J       Date:  1995-10       Impact factor: 2.349

5.  Adherence to the first-AUG rule when a second AUG codon follows closely upon the first.

Authors:  M Kozak
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the V1a vasopressin receptor.

Authors:  J Howl; X Wang; C J Kirk; M Wheatley
Journal:  Eur J Biochem       Date:  1993-04-15

7.  Oxytocin acts at V1 receptors to excite sympathetic preganglionic neurones in neonate rat spinal cord in vitro.

Authors:  E Sermasi; J H Coote
Journal:  Brain Res       Date:  1994-06-06       Impact factor: 3.252

8.  Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor.

Authors:  J C Xue; C Chen; J Zhu; S Kunapuli; J K DeRiel; L Yu; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

9.  Identification of peptide binding residues in the extracellular domains of the AT1 receptor.

Authors:  S A Hjorth; H T Schambye; W J Greenlee; T W Schwartz
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

10.  Rat testicular myoid cells express vasopressin receptors: receptor structure, signal transduction, and developmental regulation.

Authors:  J Howl; S A Rudge; R A Lavis; A R Davies; R A Parslow; P J Hughes; C J Kirk; R H Michell; M Wheatley
Journal:  Endocrinology       Date:  1995-05       Impact factor: 4.736

View more
  3 in total

1.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 2.  The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies.

Authors:  Meera E Modi; Larry J Young
Journal:  Horm Behav       Date:  2011-12-20       Impact factor: 3.587

Review 3.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.